AbbVie – Global Leader in Innovative Biopharmaceuticals

AbbVie

Country: United States

AbbVie Inc. is an American biopharmaceutical company headquartered in North Chicago, Illinois. It was separated from Abbott Laboratories and began operating independently on 1 January 2013. Its shares trade on the New York Stock Exchange (NYSE: ABBV).

AbbVie's main areas are immunology, oncology, neuroscience, aesthetics and eye care. The company is known for Humira (adalimumab), for many years one of the world's best-selling medicines, and for the immunology drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib).

Its portfolio has grown through major acquisitions: in 2015 AbbVie bought Pharmacyclics, the developer of ibrutinib (Imbruvica), and in 2020 it completed the acquisition of Allergan, the maker of Botox.

Together with Genentech (Roche Group), AbbVie developed venetoclax, the first BCL-2 inhibitor, approved by the FDA in 2016 for chronic lymphocytic leukaemia. In hepatology the company makes Maviret, a pangenotypic combination for chronic hepatitis C approved in 2017.

Unifarm carries AbbVie's medicines: Maviret (glecaprevir/pibrentasvir) and Venclyxto 100 (venetoclax).

Official manufacturer website
AbbVie

List of medicines by manufacturer AbbVie

-6%
Maviret
View
AbbVie
100 mg / 40 mg 84 tablets
131150₴ 139610₴
-7%
Venclyxto 100
View
AbbVie
100 mg 112 tablets
111750₴ 120690₴
✅ All products loaded (2)

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00